{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:43:47Z","timestamp":1791607427120,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,17]]},"DOI":"10.7759\/cureus.82457","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:04:41Z","timestamp":1744909481000},"source":"Crossref","is-referenced-by-count":2,"title":["Complete Resolution of Granulomatous Rosacea With Topical Ruxolitinib"],"prefix":"10.7759","author":[{"given":"Jeffrey D","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khoshniyati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Pierog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rozati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.03.009","article-title":"Granulomatous rosacea and periorificial dermatitis: controversies and review of management and treatment","volume":"33","author":"Lee GL","year":"2015","unstructured":"Lee GL, Zirwas MJ. Granulomatous rosacea and periorificial dermatitis: controversies and review of management and treatment. Dermatol Clin. 2015, 33:447-55. 10.1016\/j.det.2015.03.009","journal-title":"Dermatol Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45391","article-title":"Facial granulomatous rosacea: a case report","volume":"15","author":"Almutairi RS","year":"2023","unstructured":"Almutairi RS, Al-Sabah HY. Facial granulomatous rosacea: a case report. Cureus. 2023, 15:e45391. 10.7759\/cureus.45391","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802032595","article-title":"A case of granulomatous rosacea successfully treated with pimecrolimus cream","volume":"19","author":"G\u00fcl U","year":"2008","unstructured":"G\u00fcl U, G\u00f6n\u00fcl M, Kili\u00e7 A, Ko\u00e7ak O, Aslan E, Erg\u00fcl G, Kula\u00e7o\u011flu S. A case of granulomatous rosacea successfully treated with pimecrolimus cream. J Dermatolog Treat. 2008, 19:313-5. 10.1080\/09546630802032595","journal-title":"J Dermatolog Treat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S440138","article-title":"Successful treatment of granulomatous rosacea by JAK inhibitor abrocitinib: a case report","volume":"16","author":"Ren M","year":"2023","unstructured":"Ren M, Yang X, Teng Y, Lu W, Ding Y, Tao X. Successful treatment of granulomatous rosacea by JAK inhibitor abrocitinib: a case report. Clin Cosmet Investig Dermatol. 2023, 16:3369-74. 10.2147\/CCID.S440138","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani F","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019, 10:2847. 10.3389\/fimmu.2019.02847","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad188","article-title":"Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review","volume":"48","author":"Dogra S","year":"2023","unstructured":"Dogra S, Sharma A, Mehta H, Sarkar R. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review. Clin Exp Dermatol. 2023, 48:1102-12. 10.1093\/ced\/llad188","journal-title":"Clin Exp Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1239869","article-title":"JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series","volume":"10","author":"Xu B","year":"2023","unstructured":"Xu B, Xu Z, Ye S, Sun H, Zhao B, Wu N, Wu J. JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series. Front Med (Lausanne). 2023, 10:1239869. 10.3389\/fmed.2023.1239869","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1416004","article-title":"Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea","volume":"15","author":"Zhang T","year":"2024","unstructured":"Zhang T, Liu X, Zhang L, Jiang X. Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea. Front Immunol. 2024, 15:1416004. 10.3389\/fimmu.2024.1416004","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03314-4","article-title":"The treatment of tofacitinib for rosacea through the inhibition of the JAK\/STAT signaling pathway","volume":"316","author":"Sun R","year":"2024","unstructured":"Sun R, Fan H, Liu J, Gao G, Liu C, Zhang D, Ma W. The treatment of tofacitinib for rosacea through the inhibition of the JAK\/STAT signaling pathway. Arch Dermatol Res. 2024, 316:566. 10.1007\/s00403-024-03314-4","journal-title":"Arch Dermatol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674871","article-title":"Keratinocyte-immune cell crosstalk in a STAT1-mediated pathway: novel insights into rosacea pathogenesis","volume":"12","author":"Deng Z","year":"2021","unstructured":"Deng Z, Liu F, Chen M, et al.. Keratinocyte-immune cell crosstalk in a STAT1-mediated pathway: novel insights into rosacea pathogenesis. Front Immunol. 2021, 12:674871. 10.3389\/fimmu.2021.674871","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.06.013","article-title":"Targeting the STAT3\/IL-36G signaling pathway can be a promising approach to treat rosacea","author":"Meng X","year":"2024","unstructured":"Meng X, Zhong Y, Kuang X, et al.. Targeting the STAT3\/IL-36G signaling pathway can be a promising approach to treat rosacea. J Adv Res. 2024, 10.1016\/j.jare.2024.06.013","journal-title":"J Adv Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-03915-7","article-title":"Bioinformatic analysis and experimental validation implicate STAT2-mediated angiogenic responses in rosacea pathogenesis","volume":"317","author":"Chen B","year":"2025","unstructured":"Chen B, Wu C, Liao Y, et al.. Bioinformatic analysis and experimental validation implicate STAT2-mediated angiogenic responses in rosacea pathogenesis. Arch Dermatol Res. 2025, 317:398. 10.1007\/s00403-025-03915-7","journal-title":"Arch Dermatol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking AM","year":"2018","unstructured":"Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018, 79:535-44. 10.1016\/j.jaad.2018.04.018","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations","volume":"132","author":"Chu DK","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, et al.. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024, 132:274-312. 10.1016\/j.anai.2023.11.009","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/358799-complete-resolution-of-granulomatous-rosacea-with-topical-ruxolitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:04:42Z","timestamp":1744909482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/358799-complete-resolution-of-granulomatous-rosacea-with-topical-ruxolitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.82457","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}